Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanowin Plus
- Development stage
- Unknown
- Lead developer
- Microwin Labs
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Nanowin Plus is a topical pain relief gel and muscle relaxant developed and manufactured by Microwin Labs. It is formulated as a fixed-dose combination containing diclofenac diethylamine, linseed oil, methyl salicylate, and menthol. Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) to reduce prostaglandin synthesis, thereby alleviating pain and inflammation. Methyl salicylate and menthol act as counterirritants; methyl salicylate is metabolized to salicylic acid (which also inhibits COX enzymes) and activates TRPA1 and TRPV1 channels, while menthol activates TRPM8 channels to produce a cooling sensation that interferes with pain signal transmission. Linseed oil provides additional anti-inflammatory effects by inhibiting arachidonic acid metabolism. Nanowin Plus is indicated for the fast and effective relief of muscle pain, joint pain, strains, sprains, spasms, cramps, backache, sciatica, and arthritis.
- Brand names
- Nanowin Plus
- Other names
- Nanowin Plus GelNanowin Plus Pain Relief Gel
02
Targets
TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Nanowin Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanowin Plus.